Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
- EVOTEC’S EVOCELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING
GEN News: 3D Bioreactor Shows Promise for Donor Cell Therapies
A company has developed an iPhone-like bioreactor that may have the potential to aid quality control to validate the efficacy of cell therapies. The flat bioreactor, which has an inner section to hold various cell types, is designed to give a real-time 3D view of the tumor environment.Read more
Octobre 18, 2021 Outsourced Pharma: Cell And Gene Start-Ups Need "CDMO 2.0"
By Louis Garguilo, Chief Editor, Outsourced Pharma
Try as I may, I can’t get Massimo Dominici to use the term “CDMO,” although that’s what we’re talking about.
At least I think that’s what we’re talking about.
Finally, he relents; instead of saying “partnerships” again, he references “CDMO 2.0” as a different breed of external organization, established to support cell and gene therapy (CGT) companies – a prelude partner before potentially utilizing larger, established CDMOs.
Continue reading
October 12, 2021 Outsourced Pharma: Creating The Culture Of Cell Culture
By Louis Garguilo, Chief Editor, Outsourced Pharma
Massimo Dominici is co-founder of Rigenerand, a cell-and-gene therapy (CGT) company in Modena, Italy; full-time professor at University of Modena and Riggio Emilia; advisor to the World Health Organization (WHO); former Chairman of the International Society for Cell And Gene Therapy (ISCT); and licensed oncologist.Read more
Mesenchymal Stromal Stem Cells: Next Steps and Considerations for CGMP Manufacturing
Massimo Dominici is scientific founder of Rigenerand srl, a joint venture between RanD (a biomedical company producing bioreactors for liver support and chemohyperthermic technology for cancer) and experts in cell and gene therapy at the University of Modena and Emilia Region in Italy. Rigenerand develops and manufactures medicinal products for cell-therapy applications (primarily for regenerative medicine and oncology) and three-dimensional (3D) bioreactors as an alternative to animal testing for preclinical investigations. The company also produces its own pipeline of cell and gene therapies for cancer treatment and operates a contract development and manufacturing (CDMO) division that provides good manufacturing practice (GMP) support for scaling up of cell-based medicinal products. Headquartered in Medolla, Italy, Rigenerand is developing a proprietary gene therapy for treating patients with pancreatic ductal adenocarcinoma (PDAC). It has been granted orphan drug designation by both the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA), with a phase 1 clinical trial beginning this year. Read more
Rigenerand signs distribution partnership with Lacopa LLC for VITVO 3D cell culture technology
Lacopa has rights for distribution in Asian markets including Russia Modena, Italy, March 09, 2021 – Rigenerand SRL, the biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology, today announces the singing of a distribution agreement with Lacopa LLC. The agreement will enable Lacopa to distribute Rigenerand’s VITVO 3D cell culture technology across the Central Asian regions of Russia, Kazakhstan and Belarus. Rigenerand has developed VITVO as an innovative handheld bioreactor with an integrated scaffold for establishing an in vitro 3D cell culture model. It is expected that Lacopa will encounter most demand from Russian academic research teams as well as pharma companies in the region. VITVO’s 3D models will greatly enhance academic and pharma research and pre-clinical programs for cell and gene therapies. Lacopa specialists will actively work with a Rigenerand team to enhance the well-established Rigenerand distribution strategy for VITVO to specifically meet regional needs and requirements, based on an evaluation of regional client expectations in Central Asia. Read More
